aDepartment of Clinical Toxicology, Central Laboratories & Blood Bank, King Fahad Medical City, Riyadh 11525, Kingdom of Saudi Arabia
bDepartment of Clinical Pharmacology, Muhimbili College of Health Sciences, Dar es Salaam, Tanzania
cDivision of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden
dSandwich Laboratories, Pfizer Inc., Sandwich, Kent, UK
Correspondence and requests for reprints to Prof. Leif Bertilsson, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital, Huddinge, C1 68, SE-141 86 Stockholm, Sweden.
Tel: +46 8 5858 10 71; fax: +46 8 5858 10 70; e-mail: [email protected]
Sponsorship: This study was supported by grants from the Swedish Medical Research Council (3902), National Institutes of Health, USA (grant R01 GM60548), the Swedish Agency for Research Collaboration with Developing Countries (SAREC) at the Swedish International Development Cooperation Agency (SIDA) (SWE-1999-260, 99-266 Bil. Th. 106, SWE 2002-076 and SWE-2002-063 and SWE-2005-030), Pfizer Ltd, Swedish Society for Medical Research (A200100225 and A200300875) and Karolinska Institutet.
Received 30 December 2004 Accepted 14 March 2006